Galectin Therapeutics (GALT) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Galectin Therapeutics
Is Galectin Therapeutics a buy right now? The alternative data says hold. This GALT stock analysis is built on the 25+ alternative data signals AltIndex tracks on Galectin Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 47/100: a Hold. The stock trades at $3.94 with a $367M market cap.
The soft spots over the past 90 days: web traffic down 57.6% to 5K monthly visits. The rest of the signal set is holding steady, which keeps GALT at a hold rather than a sell.
GALT’s broader alt-data profile also covers headcount (36 employees, according to LinkedIn), X followers (732), and sentiment (100/100). Every signal links to its own page with full history, the GALT technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on GALT is just below.
Galectin Therapeutics AI Stock Analysis
Galectin Therapeutics (NASDAQ: GALT) is a biotechnology company focused on developing therapies for fibrotic disease and cancer. The company’s key focus is on galectin proteins, which play a significant role in various diseases. Their lead product candidate, GR-MD-02, is in clinical development for the treatment of liver fibrosis and cancer.
Analysis generated October 2, 2026.
Recent Galectin Therapeutics Stock Alerts
|
Galectin Therapeutics | October 9 Price is up by 6.3% in the last 24h. |
|
Galectin Therapeutics | October 5 Price is down by -6.4% in the last 24h. |
|
Galectin Therapeutics | September 22 Price is up by 6.1% in the last 24h. |
|
Galectin Therapeutics | September 8 Price is down by -9.7% in the last 24h. |
Galectin Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 5K | 57.6% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 36 | 0% | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 3 | 50.0% | |
| Stocktwits Mentions | 263 | 11.1% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 11K | 0% | |
| X Followers | 732 | 0% |
About Galectin Therapeutics (GALT)
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia.
| Price | $3.94 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $367M |
| Year Range | $2 – $7 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Galectin Therapeutics News
View more →
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance SheetAugust 4 - GlobeNewswire |
|
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal HypertensionJune 23 - GlobeNewswire |
|
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH CirrhosisMay 27 - GlobeNewswire |
|
 |
Obesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsightSeptember 10 - PRNewswire |
 |
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsightAugust 26 - PRNewswire |
See Galectin Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for GALT, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEGalectin Therapeutics Earnings & Financial Performance
View all earnings →Galectin Therapeutics Insider Trading Activity
View all →| Jamil Khurram filed to sell 0 shares at $0.0. Jul 14 '26 |
| Jamil Khurram filed to sell 0 shares at $0.0. Jun 23 '26 |
| Jamil Khurram filed to sell 0 shares at $0.0. May 26 '26 |
| ELDRED KARY filed to sell 65,682 shares at $0.0. Feb 6 '26 |
| Jamil Khurram filed to sell 0 shares at $0.0. Jan 6 '26 |
Galectin Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Galectin Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Arcturus TherapeuticsARCT |
$13.74 6.8% | $355M | 46 |
 |
Kyverna TherapeuticsKYTX |
$6.39 3.4% | $382M | 45 |
 |
AgenusAGEN |
$7.67 1.7% | $342M | 50 |
 |
C4 TherapeuticsCCCC |
$3.16 10.9% | $340M | 55 |
 |
OcugenOCGN |
$0.96 2.2% | $339M | 43 |
Explore Galectin Therapeutics Data
Frequently Asked Questions: Galectin Therapeutics (GALT)
Galectin Therapeutics has an AltIndex AI Score of 47/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
47/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Galectin Therapeutics (GALT) stock is $3.94 with a market cap of $367M.
As of today, Galectin Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Galectin Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Galectin Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The GALT stock price chart above shows Galectin Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Galectin Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Galectin Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
